Wedler A, Bley N, Glaß M, Müller S, Rausch A, Lederer M, Urbainski J, Schian L, Obika KB, Simon T, Peters LM, Misiak C, Fuchs T, Köhn M, Jacob R, Gutschner T, Ihling C, Sinz A, Hüttelmaier S. RAVER1 hinders lethal EMT and modulates miR/RISC activity by the control of alternative splicing. Nucleic Acids Res. 2024 Feb 1:gkae046. doi.org/10.1093/nar/gkae046. Epub ahead of print. PMID: 38300787.

  1. Glaß M, Hüttelmaier S. IGF2BP1-An Oncofetal RNA-Binding Protein Fuels Tumor Virus Propagation. Viruses. 2023 Jun 24;15(7):1431. doi.org/10.3390/v15071431. PMID: 37515119; PMCID: PMC10385356.

  2. Hagemann S, Misiak D, Bell JL, Fuchs T, Lederer MI, Bley N, Hämmerle M, Ghazy E, Sippl W, Schulte JH, Hüttelmaier S. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression. Mol Cancer. 2023 May 29;22(1):88. doi.org/10.1186/s12943-023-01792-0. PMID: 37246217; PMCID: PMC10226260.

  3. Bertoldo JB, Müller S, Hüttelmaier S. RNA-binding proteins in cancer drug discovery. Drug Discov Today. 2023 Jun;28(6):103580. doi.org/10.1016/j.drudis.2023.103580. Epub 2023 Apr 7. PMID: 37031812.